Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156819 · ClinicalTrials.gov registry record · Phase 4
The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial
A Phase 4 study, sponsored by JHSPH Center for Clinical Trials.
- Completed
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
NCT00156819 is a Phase 4 study that has completed, run by JHSPH Center for Clinical Trials. The registered enrollment target is 500 participants.
The verdict
NCT00156819, a Phase 4 study, has completed, sponsored by JHSPH Center for Clinical Trials.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
Study Summary
This research study will compare the treatment effects of three different asthma medications in asthma subjects whose asthma is well controlled when they take fluticasone, an inhaled corticosteroid. The treatments are fluticasone, montelukast (an anti?leukotriene drug), and a combination therapy of fluticasone and salmeterol (a long-acting beta-agonist). Fluticasone, montelukast, and the combination therapy of fluticasone and salmeterol (Advair Diskus®) are all approved for the treatment of asthma. We are looking at whether the three treatments are equally effective for reducing the number and the severity of asthma attacks in subjects with mild to moderately severe asthma.
Interventions
- DRUG montelukast
- DRUG fluticasone
- DRUG Fluticasone plus salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2003-06 |
| Est. Completion | 2006-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00156819
The ClinicalTrials.gov registry entry for NCT00156819 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JHSPH Center for Clinical Trials, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which montelukast is the first listed.
NCT00156819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00156819 about?
NCT00156819 is a clinical study titled "The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial". This research study will compare the treatment effects of three different asthma medications in asthma subjects whose asthma is well controlled when they take fluticasone, an inhaled corticosteroid. The treatments are fluticasone, montelukast (an anti?leukotriene drug), and a combination therapy of ...
What is the current status of trial NCT00156819?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2003-06. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00156819?
The interventions under investigation include: montelukast (DRUG), fluticasone (DRUG), Fluticasone plus salmeterol (DRUG).
Who is sponsoring clinical trial NCT00156819?
This trial is sponsored by JHSPH Center for Clinical Trials, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.